Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7976221 | 1.00 | SLC6A4 (0.60) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28296170 | 0.87 | SLC6A4 (0.69) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21323940 | 0.82 | SLC6A4 (0.62) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6017470 | 0.82 | SLC6A4 (0.62) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL13623704 | 0.82 | SLC6A4 (0.62) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL24733166 | 0.81 | SLC6A4 (0.56) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL334385 | 0.80 | SLC6A4 (0.66) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8983553 | 0.80 | SLC6A4 (0.60) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL28351383 | 0.80 | SLC6A4 (0.60) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 | |
| SCHEMBL334384 | 0.80 | SLC6A4 (0.66) | SLC6A4LDHACYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3494104-A1 | WARMING SENSATION COMPOUNDS | Takasago International Corporation (JP) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018027202-A1 | WARMING SENSATION COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (USA) (US) | 2018-02-08 | — | — | WO | disclosed |
| US-8980833-B2 | Tubulysine derivatives | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | R&D-BIOPHARMACEUTICALS GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-7619116-B2 | Intermediates for the synthesis of (R)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | Products Chimiques Auxiliaires Et de Synthese (FR) | 2009-11-17 | — | — | US | disclosed |
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129779-A1 | TUBULYSINE DERIVATIVES | GLS, TPX2, HKDC1 | SLC6A4 1280/4885LDHA 1893/4885CYP1A2 4769/4885 |
| US-20070106079-A1 | Novel intermediates for the synthesis of (r)-tamsulosin and of its pharmaceutically acceptable salts and process for their preparation | ADRB1, AVPR2, ADRA1A | SLC6A4 421/4885LDHA 3340/4885CYP1A2 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.